• Quantum BioPharma signed a study start-up agreement with Thermo Fisher’s PPD clinical research unit to implement a Phase 2 trial of Lucid-MS.
• Agreement triggers formal start-up work for a randomized, double-blind, placebo-controlled study in progressive multiple sclerosis.
• Trial will assess efficacy, safety, tolerability using clinical and radiological endpoints following FDA clearance to proceed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006429), on October 06, 2026, and is solely responsible for the information contained therein.